CTC Alternative Strategies Ltd. Takes Position in AbbVie Inc. $ABBV

Key Points

• CTC Alternative Strategies Ltd. acquired 11,400 AbbVie shares worth approximately $2.87 million in the second quarter, making ABBV about 4.2% of its portfolio and its sixth-largest holding. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie reported quarterly EPS of $3.65, exceeding estimates by $0.04, while revenue rose 10.2% year over year to $16.99 billion. The company issued third-quarter 2026 EPS guidance of $3.84–$3.88.
• ABBV shares opened at $248.75 after declining 3%, while analysts maintained a “Moderate Buy” consensus rating with an average price target of $275.95. AbbVie also pays a $1.73 quarterly dividend, yielding approximately 2.8% annually.

CTC Alternative Strategies Ltd. acquired a new position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 11,400 shares of the company's stock, valued at approximately $2,869,000. AbbVie makes up approximately 4.2% of CTC Alternative Strategies Ltd.'s investment portfolio, making the stock its 6th largest position.

Other institutional investors have also recently modified their holdings of the company. Burk Holdings LLC purchased a new position in AbbVie during the second quarter worth $30,000. Litman Gregory Wealth Management LLC purchased a new stake in shares of AbbVie in the fourth quarter valued at $28,000. Imprint Wealth LLC boosted its stake in shares of AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company's stock valued at $29,000 after acquiring an additional 45 shares during the last quarter. IFC & Insurance Marketing Inc. acquired a new stake in shares of AbbVie during the fourth quarter valued at $31,000. Finally, Marquette Asset Management LLC increased its position in AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company's stock worth $35,000 after purchasing an additional 48 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Trading Down 3.0%

Shares of NYSE:ABBV opened at $248.75 on Wednesday. The firm has a market cap of $439.49 billion, a price-to-earnings ratio of 70.27, a PEG ratio of 1.16 and a beta of 0.29. The stock's 50-day moving average price is $254.66 and its two-hundred day moving average price is $230.36. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company's quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. AbbVie's dividend payout ratio (DPR) is currently 195.48%.

Analyst Ratings Changes

Several brokerages recently weighed in on ABBV. Wolfe Research raised shares of AbbVie from a "peer perform" rating to an "outperform" rating and set a $300.00 target price for the company in a research note on Thursday, August 13th. Evercore set a $235.00 price target on shares of AbbVie in a report on Friday, May 15th. Canaccord Genuity Group boosted their price objective on shares of AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. BNP Paribas Exane upped their price objective on shares of AbbVie from $218.00 to $247.00 and gave the company a "neutral" rating in a research note on Tuesday, August 11th. Finally, Royal Bank Of Canada raised their target price on shares of AbbVie from $260.00 to $280.00 and gave the stock an "outperform" rating in a research report on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $275.95.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by corporate insiders.

AbbVie Company Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott's diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie's immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.